NASDAQ: VCEL
$ 1.85 +0.07 (3.64%)
Day High: 1.90
Day Low:  1.76
Volume:    36,340
3:59 PM ET on
Feb 12, 2016

Delayed ~20 min., by eSignal.

Press Releases

 
Press Releases
  Date Title View
Jan 4, 2016
CAMBRIDGE, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for...
Dec 8, 2015
CAMBRIDGE, Mass., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it has submitted a Humanitarian Device Exemption (HDE) supplement to the U.S. Food and Drug Administration to revise the l...
Nov 13, 2015
Total Revenues of $11.3 Million Reported for the Third QuarterCarticel and Epicel Revenues Increase 19% Compared to Third Quarter of 2014Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the t...
Nov 3, 2015
CAMBRIDGE, Mass., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What: Vericel Corporation Third-Quarter 2015 Earnings Call When...
Oct 26, 2015
Sep 23, 2015
CAMBRIDGE, Mass., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will present at the following investor conferences in late September and early October: Ladenburg Thalmann 2015 ...
Aug 12, 2015
Total Revenues of $13.6 Million Reported for the Second QuarterCarticel and Epicel Revenues Increase 31% Compared to Second Quarter 2014Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the tr...
Jul 29, 2015
CAMBRIDGE, Mass., July 29, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: ...
Jul 14, 2015
CAMBRIDGE, Mass., July 14, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that following discussions with the U.S. Food and Drug Administration (FDA), the company plans to submit a Humanitarian Device...
Jun 10, 2015
CAMBRIDGE, Mass., June 10, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that following discussions with the U.S. Food and Drug Administration (FDA) the company plans to submit a Biologics License Ap...
1
... NextLast
= add release to Briefcase